Do GLP-1 programs work for perimenopause and menopause weight gain
Based on the significant unmet need in Alzheimers disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutides potential, despite a low likelihood of success, Martin Holst Lange, chief scientific officer at Novo Nordisk said in a press release
[DOI] [PubMed] [Google Scholar] 8.Loomba R., Hartman M.L., Lawitz E.J., Vuppalanchi R., Boursier J., Bugianesi E., Yoneda M., Behling C., Cummings O.W., Tang Y., et al
No adverse effects were documented
Data are presented as the mean (SEM) of three independent experiments
Recently, it has also been approved in certain regions for chronic weight management in adults